MicroRNA-21 in Colorectal Cancer: “Just Another Brick in the Wall”?
Authors: Sebastian Stintzing, Heinz-Josef Lenz
Journal: JNCI Journal of the National Cancer Institute (2013)

MicroRNAs (miRNAs)—small, noncoding RNA strands consisting of 18 to 25 base pairs—have been investigated extensively during the last decade. Initially seen as superfluous material, it has become clear that they play a critical role in translational and posttranscriptional regulation of protein processing. In cancer cells those processes are altered and cancer cells therefore display an irregular miRNA configuration. Many solid tumors have specific patterns of miRNA expression levels, which are used in several commercially available, and, in some cases, Food and Drug Administration approved, diagnostic tests. It is possible to determine tumor origin and, in part, the histologic subtype of solid tumors by its miRNA signature. Evaluating miRNA in tissue and body fluids is therefore an emerging field of biomarker development. MicroRNA 21 (miR-21) is found to be upregulated in a wide range of solid tumors including lung, breast, gastric, colon, and glioblastoma (1), and therefore as a single marker is not specific for colon cancer. Its reported RNA targets include transforming growth factor s (TGF-s), phosphatase and tensin homolog (PTEN), programmed cell death protein 4 (PDCD4), protein sprouty 1 (Spry-1), phosphatase of regenerating liver 3 (PRL-3), and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Therefore, miR-21 may be involved in the modulation of critical steps in carcinogenesis such as proliferation, apoptosis, and migration (2). It has further been shown that colon cancer cell lines with higher expression levels of miR-21 have an enhanced ability of motility and invasion (3). Slaby and others demonstrated that tissue miR-21 expression is rising with higher Union for International Cancer Control stage (4,5) and therefore represents a marker for clinicopathologic features of the disease. First data have been published to state a role of miR-21 in chemoresistance to gemcitabine in cholangiocellular cancer cell lines (6) and 5-fluorouracil in colon cancer cells (7). Higher miR-21 tissue levels could further be linked to a decreased pathologic tumor response in patients treated with FOLFOX in a neoadjuvant setting for locally advanced colorectal cancer (CRC) (8). Owing to its capability to be secreted by cancer cells, miR-21 has been the first miRNA to be detected in the plasma in patients with diffuse large B-cell lymphoma in 2008 (9). These specifics taken together, miR21 represents an almost ideal candidate for a diagnostic tool in the diagnosis and treatment monitoring of CRC. The article by Toiyama et al. (10) in this issue of the Journal confirms previous data showing that miR-21 serum levels are higher in patients with CRC than in healthy controls (2,11). The authors showed that miR-21 levels increased with the stage of CRC. They suggested that miR-21 levels in the serum may be a useful diagnostic tool. MiR-21 serum levels were measured in 186 patients with CRC, 43 patients with advanced adenomas, and 53 healthy controls. The authors showed that miR-21 serum levels were statistically significantly higher in patients presenting with advanced adenomas or CRC compared to healthy controls. A differentiation between advanced adenomas and CRC was not achieved. Within the cohort of patients with CRC, serum levels of miR-21 were statistically significantly higher in metastatic (stage IV) disease than in stage I and II disease. Using a cutoff value determined by the receiver operating characteristic procedure, miR-21 levels had diagnostic and prognostic value. This association remained statistically significant after multivariate analysis adjusting for age, sex, TNM stage, lymph node metastasis, carcinoembryonic antigen level, distant metastasis, and pathologic differentiation. Several questions remain about the clinical use of miR-21 as a biomarker for CRC. All published miRNA data have been generated from retrospective analyses; therefore, prospective testing in independent control studies is critical for validation. Those studies should further evaluate whether miR-21 can serve as a prognostic or predictive marker in patients with CRC. It is essential to establish standardized techniques to measure serum miRNA levels. The authors tried to address this problem by